Merck Reports Results From Phase 2b/3 Clinical Trial Evaluating Clesrovimab; Results From MK-1654-004 Trial Met All Prespecified Endpoints
Merck Reports Results From Phase 2b/3 Clinical Trial Evaluating Clesrovimab; Results From MK-1654-004 Trial Met All Prespecified Endpoints
默沙東報告了從第2b/3期臨床試驗評估Clesrovimab的結果；從Mk-1654-004試驗的結果符合所有預先確定的端點
In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than 84% and 90%, respectively, through 5 months.
在2b/3期臨床試驗中，clesrovimab分別通過5個月以上降低了RSV相關住院率（次要終點）和RSV相關下呼吸道感染住院率（三級終點），分別超過84%和90%。
Clesrovimab has the potential to become the first and only approved immunization designed to protect infants with the same single dose regardless of weight for the duration of their first RSV season.
Clesrovimab有潛力成爲第一款也是唯一一款經批准的免疫設計，無論嬰兒體重如何，在他們的首個RSV季節中通過同一劑量保護。
資訊熱榜
更新時間